Emergency research rules should not require disclosure of study data, attorney says.
This article was originally published in The Gray Sheet
Executive Summary
PUBLIC DISCLOSURE OF EMERGENCY RESEARCH SHOULD BE ELIMINATED as a requirement in FDA's proposed policy on waiver of informed consent in emergency research, Jeffrey Gibbs, of the Washington, D.C. law firm Hyman, Phelps and McNamara, argues in Nov. 6 written comments to the agency. Calling for FDA to "delete" the proposed requirement for public disclosure of emergency research involving the waivers, Gibbs says that "clinical studies have historically been confidential" with "no regulatory requirement that communities be notified."
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.